Robert W. Baird cut shares of Tocagen (NASDAQ:TOCA) from an outperform rating to a neutral rating in a research note issued to investors on Thursday morning, The Fly reports.
Several other research firms have also commented on TOCA. HC Wainwright reissued a buy rating on shares of Tocagen in a report on Friday, August 9th. Zacks Investment Research lowered shares of Tocagen from a buy rating to a hold rating in a report on Wednesday, September 4th. ValuEngine raised shares of Tocagen from a hold rating to a buy rating in a report on Thursday, August 1st. Chardan Capital reissued a buy rating and issued a $10.00 target price on shares of Tocagen in a report on Wednesday, May 22nd. Finally, Citigroup began coverage on shares of Tocagen in a report on Thursday, May 30th. They issued a buy rating on the stock. Nine analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $12.95.
TOCA stock traded up $0.10 during mid-day trading on Thursday, hitting $1.03. The stock had a trading volume of 3,125,454 shares, compared to its average volume of 256,770. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.86. Tocagen has a 52 week low of $0.73 and a 52 week high of $15.80. The firm has a market capitalization of $89.61 million, a P/E ratio of -0.42 and a beta of 4.07. The firm has a fifty day simple moving average of $4.35 and a 200 day simple moving average of $7.28.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in shares of Tocagen by 72,350.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after purchasing an additional 4,341 shares during the last quarter. Creative Planning bought a new stake in shares of Tocagen during the 1st quarter valued at approximately $117,000. Parametric Portfolio Associates LLC bought a new stake in shares of Tocagen during the 2nd quarter valued at approximately $75,000. Bank of America Corp DE grew its holdings in shares of Tocagen by 28.6% during the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after purchasing an additional 3,240 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in shares of Tocagen during the 2nd quarter valued at approximately $114,000. 35.43% of the stock is currently owned by institutional investors.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.